FDA grants Fast Track designation for DiscGenics' cell therapy for disc generation

Alan Condon -   Print  |

DiscGenics received FDA Fast Track designation for its investigational cell therapy for the reduction in pain and disability linked with degenerative disc disease.

Three insights:

1. IDCT is an injectable cell therapy that use progenitor cells — known as Discogenic Cells — to provide a regenerative solution for the treatment of mild to moderate degenerative disc disease.

2. Its biomedically engineered progenitor cells are derived from intervertebral disc tissue and offer a non-invasive approach to treating the condition.

3. IDCT is currently being evaluated in clinical trials in the U.S. and Japan.

More articles on devices:
Colorado health system building orthopedic, sports medicine practice
Aurora Spine posts $3.2M in Q2 revenue: 6 things to know
Dr. Thomas Parisi, patient travel to Mexico for total knee replacement where it costs $18,000 less

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers